Literature DB >> 30964161

MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.

Y-B Gong1, X-H Fan.   

Abstract

OBJECTIVE: The aim of this study was to investigate the effect of microRNA-539-3p (miR-539-3p) on the development of epithelial ovarian cancer (EOC), and to explore the possible underlying mechanism. PATIENTS AND METHODS: A total of 40 paired EOC tissues and adjacent normal ovarian tissues were surgically resected in Hanchuan People's Hospital. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) was used to detect the expression of miR-539-3p in EOC tissues and cell lines. Targeted regulatory mechanism of miR-539-3p on SPARC-like protein 1 (SPARCL1) was identified by luciferase reporter and Western blot assays. Furthermore, the effects of miR-539-3p/SPARCL1 axis on the malignant behaviors of EOC cells, including proliferation, invasion and migration abilities, were confirmed by cell counting kit-8 (CCK-8), transwell and scratch wound assays.
RESULTS: QRT-PCR showed that the expression of miR-539-3p was significantly up-regulated in EOC tissues and cell lines. SPARCL1 was a direct target of miR-539-3p in EOC cells. Overexpression of miR-539-3p significantly promoted the proliferation, migration and invasion of SKOV3 cells. Furthermore, co-transfection of miR-539-3p inhibitor and si-SPARCL1 could remarkably restore the migration and invasion abilities of SKOV3 cells.
CONCLUSIONS: MiR-539-3p acted as an oncogene in EOC by targeting SPARCL1. MiR-539-3p/SPARCL1 axis, as a target for the treatment of EOC, might become a feasible and new method of tumor treatment.

Entities:  

Year:  2019        PMID: 30964161     DOI: 10.26355/eurrev_201903_17381

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  9 in total

1.  [MicroRNA model that can predict the prognosis of oral squamous cell carcinoma based on bioinformatics analysis].

Authors:  Ge Zhao; Chang-Xue Li; Chao Guo; Hui Zhu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-12-01

2.  The anti-tumor effect of miR-539-3p on colon cancer via regulating cell viability, motility, and nude mouse tumorigenicity with CDK14 inhibition.

Authors:  Zhuo Wang; Tao Hu; Chengwu Jin; Jiangui Yu; Dongqiang Zhu; Jian Liu
Journal:  J Gastrointest Oncol       Date:  2020-10

3.  Circular_0086414 induces SPARC like 1 (SPARCL1) production to inhibit esophageal cancer cell proliferation, invasion and glycolysis and induce cell apoptosis by sponging miR-1290.

Authors:  Qingfeng Jiang; Haoran Wang; Dongfeng Yuan; Xin Qian; Xiaochao Ma; Ming Yan; Wenqun Xing
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression.

Authors:  Jingwei Li; Wei Shao; Junhong Zhao
Journal:  Hum Cell       Date:  2020-11-16       Impact factor: 4.174

5.  Low expression of CHRDL1 and SPARCL1 predicts poor prognosis of lung adenocarcinoma based on comprehensive analysis and immunohistochemical validation.

Authors:  Huan Deng; Qingqing Hang; Dijian Shen; Yibi Zhang; Ming Chen
Journal:  Cancer Cell Int       Date:  2021-05-12       Impact factor: 5.722

6.  Extracellular Vesicle-Derived miR-105-5p Promotes Malignant Phenotypes of Esophageal Squamous Cell Carcinoma by Targeting SPARCL1 via FAK/AKT Signaling Pathway.

Authors:  Binjun He; Kang Zhang; Xiaoliang Han; Chao Su; Jiaming Zhao; Guoxia Wang; Guzong Wang; Liuya Zhang; Wenbin Hu
Journal:  Front Genet       Date:  2022-03-03       Impact factor: 4.599

7.  MiR-539-3p inhibited chondrogenic differentiation in human adipose stem cells by targeting Sox9.

Authors:  Feng Qin; Fang Wang; Xiao-Ping Wang; Jie Chen; Feng-Hua Zeng; Cui-Lan Sun; Jia-Cuo Peng Mao; Chun-Liang Li
Journal:  J Orthop Surg Res       Date:  2022-03-18       Impact factor: 2.359

Review 8.  Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine.

Authors:  Amoolya Kandettu; Divya Adiga; Vasudha Devi; Padmanaban S Suresh; Sanjiban Chakrabarty; Raghu Radhakrishnan; Shama Prasada Kabekkodu
Journal:  Genes Dis       Date:  2022-03-01

9.  miR‑539 suppresses the proliferation, migration, invasion and epithelial mesenchymal transition of pancreatic cancer cells through targeting SP1.

Authors:  Liang Xue; Yan Shen; Zhenglong Zhai; Shusen Zheng
Journal:  Int J Mol Med       Date:  2020-04-01       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.